CDMO Seqens has confirmed that its planned change of ownership has been completed, with SK Capital, a private investment firm focused on the specialty materials, chemicals and pharmaceuticals sectors, becoming the majority shareholder.

Eurazeo has announced that it has entered into exclusive discussions to sell its stake in French-based CDMO Seqens to funds advised by SK Capital Partners and its existing French shareholders, Mérieux Equity Partners.

Seqens commented that SK Capital’s involvement could enhance its position in the production of APIs, pharmaceutical intermediates and speciality ingredients. SK has already owned API manufacturer Wavelength Pharmaceuticals since 2017.